Company intelligence / Profile preview

eNeura

Sunnyvale, California, United Stateseneura.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

The company’s sTMS device has received FDA clearance for both acute and preventive treatment of migraines in adults and children aged 12 and older. Clinical results show significant reduction in headache frequency and intensity for many patients. Patient testimonials report fewer headache days, reduced pain levels, decreased use of rescue medications, improved quality of life, and the ability to return to normal activities[2].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device (specifically single-pulse transcranial magnetic stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

sTMS mini

Commercial

Indications: Migraine, Chronic migraine

Partnerships

Camden Partners Nexus (investor/partner in commercialization round)

Beyond the preview

Go deeper on eNeura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eNeura.

Explore the full profile